{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T06:45:39Z","timestamp":1648622739049},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s11886-017-0810-9","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T05:25:59Z","timestamp":1484630759000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease"],"prefix":"10.1007","volume":"19","author":[{"given":"Sara","family":"Ariotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"key":"810_CR1","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1161\/01.CIR.101.24.2823","volume":"101","author":"Y Cadroy","year":"2000","unstructured":"Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation. 2000;101:2823\u20138.","journal-title":"Circulation"},{"key":"810_CR2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","volume":"334","author":"A Schomig","year":"1996","unstructured":"Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084\u20139.","journal-title":"N Engl J Med"},{"key":"810_CR3","first-page":"1665","volume":"339","author":"MB Leon","year":"1998","unstructured":"Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators N Engl J Med. 1998;339:1665\u201371.","journal-title":"Stent Anticoagulation Restenosis Study Investigators N Engl J Med"},{"key":"810_CR4","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","volume":"98","author":"P Urban","year":"1998","unstructured":"Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998;98:2126\u201332.","journal-title":"Circulation"},{"key":"810_CR5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14656566.2016.1145666","volume":"17","author":"G Gargiulo","year":"2016","unstructured":"Gargiulo G, Moschovitis A, Windecker S, Valgimigli M. Developing drugs for use before, during and soon after percutaneous coronary intervention. Expert Opin Pharmacother. 2016;17:803\u201318.","journal-title":"Expert Opin Pharmacother"},{"key":"810_CR6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","volume":"12","author":"F Franchi","year":"2015","unstructured":"Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015;12:30\u201347.","journal-title":"Nat Rev Cardiol"},{"key":"810_CR7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357.","journal-title":"N Engl J Med"},{"key":"810_CR8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/CIRCULATIONAHA.112.124248","volume":"127","author":"P Kohli","year":"2013","unstructured":"Kohli P, Wallentin L, Reyes E, et al. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation. 2013;127:673\u201380.","journal-title":"Circulation"},{"key":"810_CR9","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.109.927582","volume":"122","author":"PG Steg","year":"2010","unstructured":"Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122:2131\u201341.","journal-title":"Circulation"},{"key":"810_CR10","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","volume":"31","author":"S James","year":"2010","unstructured":"James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31:3006\u201316.","journal-title":"Eur Heart J"},{"key":"810_CR11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","volume":"122","author":"S James","year":"2010","unstructured":"James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122:1056\u201367.","journal-title":"Circulation"},{"key":"810_CR12","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1161\/CIRCULATIONAHA.111.082727","volume":"125","author":"SK James","year":"2012","unstructured":"James SK, Storey RF, Khurmi NS, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation. 2012;125:2914\u201321.","journal-title":"Circulation"},{"key":"810_CR13","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.jacc.2014.03.031","volume":"63","author":"M Cattaneo","year":"2014","unstructured":"\u2022\u2022 Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63:2503\u20139. This study evaluated possible clinical implications derived from ticagrelor capability to increase adenosine plasma concentration (off-target properties of ticagrelor).","journal-title":"J Am Coll Cardiol"},{"key":"810_CR14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","volume":"63","author":"L Bonello","year":"2014","unstructured":"Bonello L, Laine M, Kipson N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63:872\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"810_CR15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbrc.2012.01.093","volume":"418","author":"J Ohman","year":"2012","unstructured":"Ohman J, Kudira R, Albinsson S, Olde B, Erlinge D. Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun. 2012;418:754\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"810_CR16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000347122","volume":"124","author":"K Torngren","year":"2013","unstructured":"Torngren K, Ohman J, Salmi H, Larsson J, Erlinge D. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology. 2013;124:252\u20138.","journal-title":"Cardiology"},{"key":"810_CR17","doi-asserted-by":"crossref","first-page":"h1618","DOI":"10.1136\/bmj.h1618","volume":"350","author":"EP Navarese","year":"2015","unstructured":"\u2022\u2022 Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015;350:h1618. Relevant meta-analysis of 10 DAPT trials in patients treated with DES implantation.","journal-title":"BMJ"},{"key":"810_CR18","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/eurheartj\/ehv053","volume":"36","author":"M Valgimigli","year":"2015","unstructured":"\u2022\u2022 Valgimigli M, Ariotti S, Costa F. Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus? Eur Heart J. 2015;36:1219\u201322. Critical analysis of the evidence regarding the optimal duration of DAPT after DES placement.","journal-title":"Eur Heart J"},{"key":"810_CR19","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.05.085","volume":"66","author":"D Capodanno","year":"2015","unstructured":"\u2022\u2022 Capodanno D, Gargiulo G, Buccheri S, Giacoppo D, Capranzano P, Tamburino C. Meta-analyses of dual antiplatelet therapy following drug-eluting stent implantation: do bleeding and stent thrombosis weigh similar on mortality? J Am Coll Cardiol. 2015;66:1639\u201340. First meta-analysis showing a possible differential impact of bleeding and stent thrombosis on mortality.","journal-title":"J Am Coll Cardiol"},{"key":"810_CR20","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0140-6736(14)62052-3","volume":"385","author":"S Elmariah","year":"2015","unstructured":"Elmariah S, Mauri L, Doros G, et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet. 2015;385:792\u20138.","journal-title":"Lancet"},{"key":"810_CR21","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","volume":"385","author":"T Palmerini","year":"2015","unstructured":"\u2022\u2022 Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385:2371\u201382. Essential meta-analysis, including network analysis, exploring and underlying concerns about the effects of long-term DAPT on mortality.","journal-title":"Lancet"},{"key":"810_CR22","first-page":"E603","volume":"7","author":"S Ariotti","year":"2015","unstructured":"Ariotti S, Gargiulo G, Windecker S, Valgimigli M. Time for science to catch up with clinical practice? J Thorac Dis. 2015;7:E603\u20136.","journal-title":"J Thorac Dis"},{"key":"810_CR23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2015.08.058","volume":"201","author":"F Costa","year":"2015","unstructured":"Costa F, Adamo M, Ariotti S, Navarese EP, Biondi-Zoccai G, Valgimigli M. Impact of greater than 12-month dual antiplatelet therapy duration on mortality: drug-specific or a class-effect? A meta-analysis. Int J Cardiol. 2015;201:179\u201381.","journal-title":"Int J Cardiol"},{"key":"810_CR24","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jacc.2015.05.053","volume":"66","author":"G Montalescot","year":"2015","unstructured":"\u2022 Montalescot G, Brieger D, Dalby AJ, Park SJ, Mehran R. Duration of dual antiplatelet therapy after coronary stenting: a review of the evidence. J Am Coll Cardiol. 2015;66:832\u201347. Clinical review by opinion leaders in the field of antiplatelet therapy.","journal-title":"J Am Coll Cardiol"},{"key":"810_CR25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/eurheartj\/ehv712","volume":"37","author":"T Palmerini","year":"2016","unstructured":"\u2022 Palmerini T, Stone GW. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence. Eur Heart J. 2016;37:353\u201364. Clinical review by opinion leaders in the field of antiplatelet therapy.","journal-title":"Eur Heart J"},{"key":"810_CR26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ahj.2016.01.015","volume":"174","author":"G Gargiulo","year":"2016","unstructured":"Gargiulo G, Costa F, Ariotti S, et al. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. Am Heart J. 2016;174:95\u2013102.","journal-title":"Am Heart J"},{"key":"810_CR27","first-page":"390","volume":"37","author":"JA Udell","year":"2016","unstructured":"\u2022\u2022 Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37:390\u20139. Relevant meta-analysis focused on the long-term DAPT administration in patients with previous myocardial infarction.","journal-title":"Eur Heart J"},{"key":"810_CR28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","volume":"65","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65:805\u201315.","journal-title":"J Am Coll Cardiol"},{"key":"810_CR29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","volume":"9","author":"S Ariotti","year":"2016","unstructured":"Ariotti S, Adamo M, Costa F, et al. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: a pre-specified analysis from the ZEUS trial. JACC Cardiovasc Interv. 2016;9:426\u201336.","journal-title":"JACC Cardiovasc Interv"},{"key":"810_CR30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","volume":"65","author":"M Gilard","year":"2015","unstructured":"Gilard M, Barragan P, Noryani AA, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;65:777\u201386.","journal-title":"J Am Coll Cardiol"},{"key":"810_CR31","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","volume":"125","author":"M Valgimigli","year":"2012","unstructured":"Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125:2015\u201326.","journal-title":"Circulation"},{"key":"810_CR32","doi-asserted-by":"crossref","first-page":"e003145","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","volume":"9","author":"Y Han","year":"2016","unstructured":"Han Y, Xu B, Xu K, et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 Trial. Circ Cardiovasc Interv. 2016;9:e003145.","journal-title":"Circ Cardiovasc Interv"},{"key":"810_CR33","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","volume":"9","author":"SJ Hong","year":"2016","unstructured":"Hong SJ, Shin DH, Kim JS, et al. 6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JACC Cardiovasc Interv. 2016;9:1438\u201346.","journal-title":"JACC Cardiovasc Interv"},{"key":"810_CR34","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","volume":"64","author":"A Colombo","year":"2014","unstructured":"Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086\u201397.","journal-title":"J Am Coll Cardiol"},{"key":"810_CR35","first-page":"2510","volume":"310","author":"F Feres","year":"2013","unstructured":"Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:2510\u201322.","journal-title":"JAMA"},{"key":"810_CR36","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","volume":"36","author":"S Schulz-Schupke","year":"2015","unstructured":"Schulz-Schupke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12\u00a0months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015;36:1252\u201363.","journal-title":"Eur Heart J"},{"key":"810_CR37","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","volume":"125","author":"HC Gwon","year":"2012","unstructured":"Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505\u201313.","journal-title":"Circulation"},{"key":"810_CR38","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","volume":"60","author":"BK Kim","year":"2012","unstructured":"Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60:1340\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"810_CR39","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","volume":"384","author":"JP Collet","year":"2014","unstructured":"Collet JP, Silvain J, Barthelemy O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet. 2014;384:1577\u201385.","journal-title":"Lancet"},{"key":"810_CR40","first-page":"365","volume":"37","author":"G Helft","year":"2016","unstructured":"Helft G, Steg PG, Le Feuvre C, et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J. 2016;37:365\u201374.","journal-title":"Eur Heart J"},{"key":"810_CR41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","volume":"129","author":"CW Lee","year":"2014","unstructured":"Lee CW, Ahn JM, Park DW, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2014;129:304\u201312.","journal-title":"Circulation"},{"key":"810_CR42","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"\u2022\u2022 Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155\u201366. Largest trial on long-term DAPT in patients treated with DES implantation.","journal-title":"N Engl J Med"},{"key":"810_CR43","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","volume":"67","author":"RF Storey","year":"2016","unstructured":"Storey RF, Angiolillo DJ, Bonaca MP, et al. Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. J Am Coll Cardiol. 2016;67:1145\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"810_CR44","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/eurheartj\/ehq326","volume":"31","author":"KA Fox","year":"2010","unstructured":"Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J. 2010;31:2755\u201364.","journal-title":"Eur Heart J"},{"key":"810_CR45","unstructured":"\u2022\u2022 Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2016. Most recent meta-analysis on DAPT therapy accompanying and guiding American recommendations."},{"key":"810_CR46","first-page":"1274","volume":"373","author":"MP Bonaca","year":"2015","unstructured":"\u2022\u2022 Bonaca MP, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;373:1274\u20135.","journal-title":"N Engl J Med"},{"key":"810_CR47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267\u2013315.","journal-title":"Eur Heart J"},{"key":"810_CR48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jamacardio.2016.1017","volume":"1","author":"MP Bonaca","year":"2016","unstructured":"Bonaca MP, Bhatt DL, Oude Ophuis T, et al. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial. JAMA Cardiol. 2016;1:425\u201332.","journal-title":"JAMA Cardiol"},{"key":"810_CR49","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/eurheartj\/ehv531","volume":"37","author":"MP Bonaca","year":"2016","unstructured":"Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016;37:1133\u201342.","journal-title":"Eur Heart J"},{"key":"810_CR50","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","volume":"67","author":"DL Bhatt","year":"2016","unstructured":"Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67:2732\u201340.","journal-title":"J Am Coll Cardiol"},{"key":"810_CR51","first-page":"400","volume":"37","author":"G Magnani","year":"2016","unstructured":"Magnani G, Storey RF, Steg G, et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016;37:400\u20138.","journal-title":"Eur Heart J"},{"key":"810_CR52","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2006.03.067","volume":"48","author":"J Saw","year":"2006","unstructured":"Saw J, Bhatt DL, Moliterno DJ, et al. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol. 2006;48:1567\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"810_CR53","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/cvr\/cvv173","volume":"107","author":"G Esposito","year":"2015","unstructured":"Esposito G, Schiattarella GG, Perrino C, et al. Dermcidin: a skeletal muscle myokine modulating cardiomyocyte survival and infarct size after coronary artery ligation. Cardiovasc Res. 2015;107:431\u201341.","journal-title":"Cardiovasc Res"},{"key":"810_CR54","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1016\/j.ijcard.2012.06.055","volume":"167","author":"G Giugliano","year":"2013","unstructured":"Giugliano G, Di Serafino L, Perrino C, et al. Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with peripheral arterial disease. Int J Cardiol. 2013;167:2566\u201371.","journal-title":"Int J Cardiol"},{"key":"810_CR55","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","volume":"67","author":"MP Bonaca","year":"2016","unstructured":"Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016;67:2719\u201328.","journal-title":"J Am Coll Cardiol"},{"key":"810_CR56","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.2811","author":"A Franzone","year":"2016","unstructured":"Franzone A, Piccolo R, Gargiulo G, et al. Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY randomized clinical trial. JAMA Cardiol. 2016; doi: 10.1001\/jamacardio.2016.2811 .","journal-title":"JAMA Cardiol"},{"key":"810_CR57","doi-asserted-by":"crossref","unstructured":"Bonaca MP, Goto S, Bhatt DL et al. Prevention of stroke with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation 2016.","DOI":"10.1161\/CIRCULATIONAHA.116.024637"},{"key":"810_CR58","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1056\/NEJMc1508692","volume":"373","author":"F Costa","year":"2015","unstructured":"Costa F, Valgimigli M. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;373:1271\u20132.","journal-title":"N Engl J Med"},{"key":"810_CR59","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706\u201317.","journal-title":"N Engl J Med"},{"key":"810_CR60","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","volume":"49","author":"DL Bhatt","year":"2007","unstructured":"Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"810_CR61","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.2110","author":"MP Bonaca","year":"2016","unstructured":"Bonaca MP, Sabatine MS. Antiplatelet therapy for long-term secondary prevention after myocardial infarction. JAMA Cardiol. 2016; doi: 10.1001\/jamacardio.2016.2110 .","journal-title":"JAMA Cardiol"},{"key":"810_CR62","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.2252","author":"JA Bittl","year":"2016","unstructured":"Bittl JA, Bates ER, Kaul S. Extended dual antiplatelet therapy in patients with prior myocardial infarction. JAMA Cardiol. 2016; doi: 10.1001\/jamacardio.2016.2252 .","journal-title":"JAMA Cardiol"},{"key":"810_CR63","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","volume":"315","author":"RW Yeh","year":"2016","unstructured":"\u2022\u2022 Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735\u201349. First score created to balance both ischemic and bleeding risk to be considered in the decision-making of the DAPT prolongation or interruption over 12 months after PCI.","journal-title":"JAMA"},{"key":"810_CR64","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.jacc.2016.03.485","volume":"67","author":"DJ Kereiakes","year":"2016","unstructured":"Kereiakes DJ, Yeh RW, Massaro JM, et al. DAPT score utility for risk prediction in patients with or without previous myocardial infarction. J Am Coll Cardiol. 2016;67:2492\u2013502.","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-017-0810-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T04:25:05Z","timestamp":1498364705000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-017-0810-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1007\/s11886-017-0810-9","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"article-number":"2"}}